论文部分内容阅读
几年来应用重组和类淋巴母细胞α-干扰素(IFN-a)治疗慢性HBV感染的病人的经验已肯定了IFN的疗效。但是其有效率为25～50％,表明试验的参与者存在差异性。作者对随机选择的114例成人慢性HBV携带者用重组IFN-α 2a或类淋巴母细胞IFN-α治疗,总剂量90～365×10~6U/m~2体表面积,每周3次,疗程12周以上。根据此114例的资料,对21项治疗前指标预测IFN
The experience of using recombinant and lymphoblastoid interferon-alpha (IFN-a) in the treatment of patients with chronic HBV infection over the years has affirmed the efficacy of IFN. However, its effectiveness ranged from 25% to 50%, indicating differences in participants in the trial. The authors randomized a total of 114 patients with chronic HBV carriers of IFN-α 2a or lymphoblastoid IFN-α treatment, the total dose of 90 ~ 365 × 10 ~ 6U / m ~ 2 body surface area, three times a week, treatment 12 weeks or more. Based on the data of 114 cases, predictive value of IFN for 21 pretreatment indicators was obtained